KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

News > Business News

Audio By Carbonatix

4:05 AM on Thursday, September 4

The Associated Press

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep 4, 2025--

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025.

The webcast can be accessed on the Investors section of the Company’s website at Kalvista.com. A replay will be available for at least 30 days following the event.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY ®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250904776900/en/

CONTACT: Investors:

Ryan Baker

Head, Investor Relations

(617) 771-5001

[email protected]:

Molly Cameron

Director, Corporate Communications

(857) 356-0164

[email protected]

KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: RESEARCH INFECTIOUS DISEASES BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE